Data on mRNA vaccines sent by Moderna to European regulators before the COVID-19 outbreak included early tests of the mRNA ...

An image that is spreading widely online claims that Moderna had created its COVID-19 vaccine two years before the pandemic ...

An experimental vaccine for kidney cancer is off to a promising start. In data from a Phase I trial released this week, the ...

Run by husband-and-wife team Ugur Sahin and his wife Ozlem ... choosing the most promising of four potential mRNA vaccines from BioNTech. Both Moderna and Pfizer’s shots aced the quickly ...

A Massachusetts biopharma giant is at the center of preparations already underway if bird flu mutates and begins to find ...

Shares of vaccine maker Moderna fell Wednesday as Goldman Sachs lowered its rating after the biotech’s second cut to product revenue guidance in six months.

Moderna is the only company in its peer group burning cash at an alarming rate. Click here to read more about MRNA stock and ...

Jared Holz, Mizuho Healthcare Sector strategist, joins 'Closing Bell Overtime' to talk Moderna and Novo Nordisk.

As Moderna maps out a more cautious future amid lower-than-expected sales of its current products, the company is bolstering ...

At the healthcare conference, Moderna lowered expected 2025 revenue to the range of $1.5 billion to $2.5 billion -- down from a September forecast of $2.5 billion to $3.5 billion. And Moderna said it ...

Moderna's mRNA platform has enabled the development of therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases and autoimmune diseases. With a unique culture and a global ...